Amlitelimab, Sanofi’s Anti-OX40L Antibody, Hits All Primary and Key Secondary Endpoints in Phase 3 AD Trial
Amlitelimab, Sanofi’s anti-OX40L antibody, met all primary and key secondary endpoints in a Phase 3 study of patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).